Gender dysphoria names the clinically significant distress that can arise when a person's experienced gender does not align with the sex assigned at birth, and it is the distress — not the identity itself — that anchors the DSM-5-TR diagnosis. The construct was renamed from "gender identity disorder" in DSM-5 to depathologize gender variance while preserving access to medically necessary care, and ICD-11 took a parallel step by relocating Gender Incongruence out of the mental disorders chapter and into a new chapter on conditions related to sexual health. Adolescent and adult presentations differ in important ways: adult dysphoria is typically stable when it has persisted past puberty, while adolescent presentations are more heterogeneous in trajectory and complicated by developmental timing, family dynamics, and rapidly evolving policy. Gender-affirming care — comprising psychological support, social transition, pubertal suppression in adolescents, gender-affirming hormone therapy, and surgical interventions — is endorsed as the standard-of-care framework by every major professional society that has issued a guideline, although the certainty of the evidence varies markedly across components. Clinicians should be fluent in the DSM-5-TR criteria, the WPATH Standards of Care framework, the safety profile of GnRH analogues and cross-sex hormones, and the specific suicidality and minority-stress risks that drive the mental-health burden in this population. The bottom line: diagnose the distress, do not pathologize the identity, and route care through a multidisciplinary team aligned with current guidelines while keeping a clear-eyed view of where the evidence is strong and where it remains limited.

Prevalence estimates have risen substantially in the past decade across clinic-referral data and population surveys, driven by both genuine increases in disclosure and changes in measurement. Estimates remain sensitive to the question wording used.

Population estimates

• Adult population surveys using direct identity questions estimate that roughly 0.3-0.6% of adults identify as transgender, with higher figures in younger cohorts.^[1-2]
• U.S. CDC Behavioral Risk Factor Surveillance System data estimate about 0.6% of adults identify as transgender, with adolescents and young adults reporting higher rates.^[2]
• Clinic referrals to specialist gender services in Western Europe and North America have increased severalfold since the mid-2000s, with a marked rise in adolescent referrals — particularly adolescents assigned female at birth.^[3]

Demographics and onset

• Two broad onset patterns are described: early-onset (childhood) dysphoria that persists into adolescence, and later-onset dysphoria emerging at or after puberty; both are recognized in DSM-5-TR.^[4]
• Historical clinic samples showed a male-assigned-at-birth predominance, but recent adolescent cohorts show a reversal, with assigned-female-at-birth referrals outnumbering assigned-male.^[3]

Comorbidity

• Mood and anxiety disorders are the most common comorbidities, affecting a majority of clinic-referred adolescents and adults.^[5]
• Suicidal ideation and self-harm are markedly elevated relative to cisgender peers, with lifetime suicide attempt rates in U.S. survey data approaching 40% among transgender adults.^[6]
• Autism spectrum disorder co-occurs more frequently in gender-dysphoric youth than in the general population, with several-fold elevations across multiple clinical samples.^[7]
• Substance use disorders, eating disorders, and post-traumatic stress are also overrepresented, in part reflecting minority-stress exposure.^[5-6]

Risk and protective factors

• Family rejection, school victimization, and discrimination are the dominant modifiable drivers of psychiatric morbidity.^[6,8]
• Family acceptance, school support, and access to gender-affirming care are associated with reduced depression and suicidality across observational studies.^[8]

There is no single biological pathway that explains gender identity, and dysphoria is best understood as a developmental phenomenon shaped by neurobiology, prenatal hormonal exposures, genetics, and psychosocial context. Current models are integrative rather than reductive.

Neurobiology

• Neuroimaging studies report partial shifts in cortical thickness, white-matter microstructure, and functional connectivity in transgender individuals toward patterns more typical of the experienced gender, though effects are modest and overlap with cisgender controls is substantial.^[9]
• The bed nucleus of the stria terminalis and several hypothalamic nuclei have historically been the focus of post-mortem work suggesting sex-atypical patterns in transgender adults, but sample sizes are small and findings remain preliminary.^[9]

Prenatal hormonal exposure

• Higher rates of gender dysphoria in individuals with Congenital adrenal hyperplasia (46,XX exposed to elevated androgens in utero) support a role for prenatal androgen exposure in shaping gendered behavior, although most affected individuals identify with their assigned sex.^[10]
• Animal models and rare disorders of sex development converge on a window of organizational hormonal effects on the developing brain that is distinct from later activational effects.^[10]

Genetics

• Twin studies suggest moderate heritability of gender identity and gender-variant behavior, with monozygotic concordance higher than dizygotic.^[10]
• Candidate-gene studies of androgen-receptor and estrogen-receptor polymorphisms have produced inconsistent results, and no robust GWAS hits have emerged at current sample sizes.^[10]

Psychosocial and developmental factors

• Family environment, peer relationships, and broader cultural recognition of gender diversity shape the expression and timing of identity disclosure but are not, on current evidence, causal of the underlying identity.^[8]
• Minority-stress models attribute the excess psychiatric morbidity in transgender populations to chronic exposure to stigma, discrimination, and concealment rather than to gender identity itself.^[6,8]

Integrative model

• A useful synthesis treats gender identity as the product of probabilistic interactions between prenatal neuroendocrine influences, genetic background, and postnatal experience, with the clinical phenotype of dysphoria emerging where identity and embodied or socially assigned sex are misaligned in a context that does not accommodate the mismatch.^[9-11]

DSM-5-TR codes gender dysphoria separately for children and for adolescents/adults, and the diagnosis requires both a marked incongruence between experienced and assigned gender and clinically significant distress or functional impairment. Identity alone, in the absence of distress or impairment, is not a disorder.

Adolescent and adult criteria

• A marked incongruence between experienced/expressed gender and assigned gender lasting at least six months, manifested by at least two of the following: incongruence between experienced gender and primary or secondary sex characteristics; a strong desire to be rid of one's primary or secondary sex characteristics; a strong desire for the sex characteristics of the other gender; a strong desire to be of the other (or an alternative) gender; a strong desire to be treated as the other gender; a strong conviction that one has typical feelings and reactions of the other gender.^[4]
• The condition is associated with clinically significant distress or impairment in social, occupational, or other important areas of functioning.^[4]

Specifiers

• With a disorder/difference of sex development — coded when an intersex condition (for example, congenital adrenal hyperplasia, androgen insensitivity syndrome) coexists.^[4]
• Posttransition — used when the individual is living full-time in the desired gender and has undergone, or is preparing for, gender-affirming medical or surgical treatment, and continues to require treatment.^[4]

ICD-11 differences

• ICD-11 uses the term Gender Incongruence (codes HA60 for adolescents/adults and HA61 for childhood) and places it in the chapter on conditions related to sexual health rather than in the mental and behavioural disorders chapter.^[12]
• ICD-11 deliberately removed the distress requirement to depathologize the condition while preserving the diagnostic code needed for access to gender-affirming care.^[12]

Presentations vary widely across age, developmental stage, and cultural context, but a number of features recur often enough to anchor a clinical interview. The shape of the distress matters more than any single behavior.

Core experiential features

• Persistent dissonance between experienced gender and assigned sex, often intensifying at puberty as secondary sex characteristics emerge.^[4-5]
• Distress focused on specific body features (breasts, voice, facial hair, genitals) is common and often a target of medical or surgical intervention.^[5]
• Social dysphoria — distress triggered by being addressed, perceived, or treated according to assigned gender — is frequently as impairing as anatomical dysphoria.^[5]

Adolescent-specific features

• Onset may be early (continuous from childhood) or peripubertal, and trajectory is more variable in adolescents than in adults.^[3,5]
• Co-occurring autism, anxiety, depression, and trauma histories are common and complicate assessment but do not preclude the diagnosis.^[5,7]
• Family conflict, school distress, and online community influences are typical context features that must be characterized but are not, by themselves, diagnostic.^[8]

Adult-specific features

• In adults, dysphoria that has persisted past puberty tends to be stable; late-presenting adults often describe years of concealment before disclosure.^[5]
• Many adults present for the first time seeking specific medical or surgical interventions rather than psychiatric care per se.^[5]

Course and red flags

• Acute worsening of dysphoria at puberty, after a forced detransition, or after social rejection is a recognized risk period for suicidality.^[6]
• New-onset dysphoria in the setting of acute psychosis, severe dissociation, or a primary eating disorder warrants careful differential workup before attributing symptoms to gender dysphoria alone.^[5]

The diagnostic task is to distinguish authentic gender dysphoria from psychiatric conditions that can produce body-related distress, identity confusion, or cross-gender behavior, while not dismissing genuine dysphoria when comorbid conditions are present. Comorbidity is the rule, not the exception.

Psychiatric mimics and comorbidities

• Body dysmorphic disorder — distress is focused on perceived defects in appearance rather than on gendered features per se, and the desire is for cosmetic correction within one's assigned sex.^[5]
• Transvestic disorder — sexual arousal related to cross-dressing without a sustained cross-gender identity; can co-occur with gender dysphoria but is distinct.^[4]
• Psychotic disorders — delusional beliefs about being the other sex are rare and are usually embedded in broader psychotic phenomenology with disorganized thought or other Schneiderian features.^[5]
• Dissociative identity disorder — gender-variant alters can appear in DID; the diagnosis is suggested by amnesia, identity discontinuity, and trauma history.^[5]
• Autism spectrum disorder — frequently co-occurs with gender dysphoria; both diagnoses can and should be made when criteria are met, but rigid interests in cross-gender presentation alone do not establish dysphoria.^[7]
• Adjustment disorder — distress about gender norms in the context of an acute stressor or developmental transition may not meet the duration and pervasiveness criteria for gender dysphoria.^[4]

Medical and substance-induced considerations

• Disorders or differences of sex development should be screened for in any patient with ambiguous genitalia, atypical pubertal development, or known karyotype anomalies; the DSD specifier is applied when present.^[4,10]
• Endocrine disorders affecting androgen or estrogen exposure (for example, polycystic ovary syndrome, androgen-secreting tumors) can shape secondary sex characteristics and influence body-related distress.^[10]
• Substance- or medication-induced mood states (anabolic steroids, high-dose corticosteroids) can transiently alter gendered self-experience and should be excluded before attributing presentations to gender dysphoria alone.^[5]

Assessment is a structured clinical interview, not a checklist or a gatekeeping exercise. The goals are to establish the diagnosis, characterize comorbidity, assess capacity and consent, and align the treatment plan with the patient's goals and developmental stage.

Interview structure

• Begin with open-ended history of gender development from earliest memory through current presentation, covering identity, expression, body experience, and social role.^[13]
• Characterize the timeline: age of first awareness, age of disclosure, persistence and consistency, and any periods of resolution or fluctuation.^[13]
• Map current distress across body, social, and anticipatory domains; ask about specific medical or surgical goals.^[13]

Mandatory history elements

• Psychiatric history, suicide risk, self-harm, and substance use, with attention to discrimination and minority-stress exposures.^[6,8]
• Sexual history, including sexual orientation (independent of gender identity), sexual function, and reproductive goals.^[13]
• Medical history with attention to fertility implications, family history of hormone-sensitive cancers and thromboembolism, and prior hormonal treatment from any source.^[13-14]
• Social history including family acceptance, housing stability, school or work context, legal documentation, and access to care.^[8,13]

Validated instruments

• The Utrecht Gender Dysphoria Scale and the Gender Identity/Gender Dysphoria Questionnaire are commonly used to quantify dysphoria but are not required for diagnosis.^[13]
• Standard depression, anxiety, suicidality, and substance-use screens (for example, PHQ-9, GAD-7, C-SSRS, AUDIT) should be administered routinely given comorbidity rates.^[5-6]

Physical exam and labs

• A baseline physical exam is appropriate but a genital exam is not required to make the diagnosis and should be deferred unless clinically indicated and consented.^[13]
• Baseline labs before Gender-affirming hormone therapy typically include CBC, comprehensive metabolic panel, lipids, hemoglobin A1c, prolactin, total testosterone, estradiol, and either LH/FSH or a pregnancy test where relevant; the panel mirrors endocrine society guidance.^[14]
• For adolescents considered for pubertal suppression, Tanner staging, bone age, and bone density baselines are standard.^[14-15]

What not to order

• Karyotyping, brain MRI, and hormone panels are not required to establish the diagnosis in the absence of features suggesting a DSD, an intracranial process, or an endocrine disorder.^[13]
• Psychological testing is not a gatekeeping requirement under current major guidelines; testing is reserved for clarifying differential diagnosis or comorbidity.^[13,15]

Treatment is individualized, staged, and grounded in shared decision-making. The dominant clinical framework is gender-affirming care as articulated in the WPATH Standards of Care version 8 and the Endocrine Society clinical practice guideline, with national guidelines (NICE, Swedish National Board of Health and Welfare, Finnish COHERE) offering more cautious adolescent-specific guidance.

Pharmacotherapy

• Gender-affirming hormone therapy is the cornerstone of medical transition in adults and is commonly recommended; evidence suggests it reduces dysphoria and improves psychological functioning across observational studies, though randomized data are limited.^[14,16]
• Feminizing therapy typically uses estradiol 2-6 mg PO QD or transdermal estradiol with an anti-androgen such as spironolactone 100-200 mg PO QD or, in some regions, cyproterone acetate.^[14]
• Masculinizing therapy uses testosterone 50-100 mg IM weekly (cypionate or enanthate) or transdermal testosterone titrated to physiologic male range.^[14]
• GnRH analogues such as leuprolide 11.25 mg IM q3 months or histrelin implants are used for pubertal suppression in adolescents at Tanner stage 2 or later under specialist supervision; evidence suggests reduced dysphoria but certainty regarding long-term mental-health and bone outcomes is low.^[15,17]
• Adjunctive psychotropic treatment of comorbid depression, anxiety, ADHD, or PTSD follows standard disorder-specific guidelines and should not be delayed pending decisions about transition.^[5,13]

Psychotherapy

• Supportive, exploratory, and skills-based psychotherapies are commonly recommended to assist with identity exploration, decision-making about medical interventions, family work, and treatment of comorbid conditions.^[13,18]
• Cognitive-behavioral approaches adapted for minority-stress exposure have moderate evidence for reducing depression and anxiety in transgender adults.^[18]
• Family-based therapy and parental psychoeducation are commonly recommended for adolescents given the central role of family acceptance in outcome.^[8,15]
• Conversion or "reparative" therapies aimed at changing gender identity are ineffective and harmful and are not a legitimate treatment option.^[13,19]

Surgical and procedural

• Gender-affirming surgeries — including chest reconstruction (mastectomy or breast augmentation), genital surgeries (vaginoplasty, phalloplasty, metoidioplasty), facial feminization, and hysterectomy/orchiectomy — are commonly recommended for adults who meet WPATH criteria; observational evidence suggests improved body satisfaction and reduced dysphoria, with low rates of regret in adult cohorts.^[16,20]
• Voice therapy, hair removal, and other ancillary procedures are routinely incorporated into transition care.^[13]
• Surgical interventions in minors are restricted in most guidelines to chest surgery in older adolescents on a case-by-case basis; genital surgery in minors is generally not recommended.^[13,15]

Neuromodulation

• There is no role for neuromodulation as a treatment for gender dysphoria itself; ECT, rTMS, and similar interventions are used only for severe comorbid mood disorders following standard indications.^[5]

Adjunctive

• Fertility preservation counseling (sperm banking, oocyte cryopreservation) should be offered before initiating hormonal interventions that may impair gonadal function.^[14-15]
• Social transition support — name and pronoun use, legal documentation, school and workplace accommodations — is a low-risk, often high-impact intervention.^[8,13]
• Peer support and community connection are associated with improved outcomes in observational data and are routinely recommended adjuncts.^[8]

The harms picture for gender dysphoria care has two layers: the direct adverse effects of medical interventions, and the limitations of the evidence that informs them. Both deserve frank discussion in consent conversations and in the chart.

Common adverse effects of medical care

• Estrogen regimens carry dose-dependent VTE risk, hyperprolactinemia, weight gain, mood lability during titration, and reduced libido. ^[13-14]
• Testosterone produces acne, androgenic alopecia, erythrocytosis requiring periodic hematocrit monitoring, dyslipidemia, and pelvic cramping or vaginal atrophy. ^[13-14]
• GnRH analogues in adolescents are associated with attenuated bone mineral density accrual that may not fully recover, hot flashes, mood symptoms, and injection-site reactions. ^[4,15]

Serious or rare adverse effects

• Estrogen-related VTE, cerebrovascular events, and cardiovascular events, especially in smokers and those over 40. ^[13]
• Testosterone-related polycythemia with secondary thrombotic risk. ^[13]
• Surgical complications including urethral fistula and stenosis after phalloplasty or vaginoplasty, neovaginal prolapse, and wound dehiscence. ^[16]
• Regret, although low in published cohorts (commonly under 1 percent over 5-10 years for adults who completed comprehensive assessment), is not zero, and modern regret data on adolescent-onset and rapid-presentation cohorts remain immature. ^[16,18]

Monitoring burden and discontinuation

• Hormonal regimens require lifelong monitoring of hormone levels, lipids, hematocrit, liver enzymes, blood pressure, and bone density. ^[13]
• Discontinuation of cross-sex hormones leads to partial regression of reversible secondary sex characteristics but preserves irreversible changes (voice deepening, clitoromegaly, breast tissue), which complicates detransition trajectories. ^[16]
• Adherence is often complicated by access barriers, insurance coverage gaps, and pharmacy interruptions. ^[4]

Limitations of the evidence base

• Most outcome studies are observational cohorts, often single-center, with selection bias toward patients who complete assessment and remain in care. ^[18-19]
• Randomized trials are largely absent for ethical and feasibility reasons, leaving causal inference about long-term mental-health benefit constrained. ^[19]
• Follow-up beyond 10 years is sparse, especially for the contemporary cohort of adolescents presenting after 2015. ^[19-20]
• Reporting of detransition and regret is inconsistent across studies; case ascertainment depends on patients returning to the original clinic. ^[18,20]

Gender dysphoria intersects with developmental stage, reproductive biology, and comorbidity in ways that meaningfully change the clinical plan. The differences below are not optional flourishes; they are where treatment errors most often occur.

Children and prepubertal presentations

• Prepubertal childhood gender dysphoria is heterogeneous in trajectory; longitudinal data from earlier cohorts show that a substantial minority of gender-variant children do not persist into adolescence, although those who do persist are highly likely to continue into adulthood. ^[4,8]
• No medical interventions are indicated before puberty; care centers on family education, exploratory psychotherapy, and support for social-transition decisions if the family chooses. ^[4]
• Aggressive efforts to enforce conformity to assigned sex are associated with worse mental-health outcomes and are not recommended. ^[3-4]

Adolescents

• Adolescent presentations have risen sharply in incidence since approximately 2015, with a marked shift toward natal-female presentation and later onset; the drivers of this shift are debated. ^[8,20]
• Comorbid Autism spectrum disorder, depression, anxiety, eating disorders, and ADHD are common and must be assessed and concurrently treated, not used to dismiss the dysphoria. ^[4,8]
• Pubertal suppression with leuprolide 11.25 mg IM q12 weeks or histrelin implant is initiated at Tanner stage 2 or later by an experienced pediatric endocrinologist within a multidisciplinary team. ^[4,15]
• Cross-sex hormones are typically considered at age 16 in classical Endocrine Society guidance, with some flexibility downward in selected cases; surgical interventions other than chest masculinization are generally deferred to adulthood. ^[4]

Perinatal and reproductive considerations

• Fertility preservation counseling is offered to all patients before initiating pubertal suppression or cross-sex hormones, because hormonal regimens reduce reproductive capacity and the timing of fertility loss is imperfectly characterized. ^[4,13]
• Pregnancy is possible in patients on testosterone whose menses have ceased; contraception counseling is essential and testosterone should be discontinued if pregnancy occurs. ^[13]
• Chestfeeding and lactation considerations apply to patients who have undergone or are considering chest surgery. ^[13]

Older adults

• Older adults presenting with new or long-standing dysphoria face higher baseline cardiovascular and thrombotic risk that should shape estrogen dosing decisions. ^[13]
• Late-life social transition is feasible and associated with improved well-being in cohort data, though long-term mental-health data in this subgroup are sparse. ^[18]

Cultural and structural factors

• Outcomes are strongly shaped by family acceptance, peer support, and access to care; minority stress models account for a substantial fraction of mental-health disparities in this population. ^[6,11]
• Legal recognition, insurance coverage, and clinician availability vary widely; clinicians should be aware of jurisdictional restrictions affecting adolescent care. ^[4,20]

Long-term outcomes vary by age of onset, comorbidity, and the timing and completeness of gender-affirming care. The overall picture is more favorable than the historical literature suggested, while remaining sobering on suicidality.

• Adult-onset dysphoria that has persisted past puberty is typically stable in identity; identity reversal after completed adult gender-affirming care is uncommon. ^[16,18]
• In adult cohorts who completed comprehensive assessment and proceeded with hormonal or surgical care, regret rates are consistently reported under 2 percent over follow-up periods of 5-10 years, with most regret attributed to social rejection rather than identity reversal. ^[16,18]
• Adolescent cohorts show high rates of progression from pubertal suppression to cross-sex hormones (often above 95 percent in published series), which is interpreted variably as appropriate continuation of care or as evidence of selection effects. ^[15,20]
• Depression, anxiety, and suicidality typically improve after initiation of gender-affirming care, though baseline rates remain elevated relative to the general population even after treatment. ^[6,11,18]
• Detransition is a heterogeneous phenomenon encompassing identity change, social factors (family pressure, safety, access loss), and medical side effects; contemporary detransition data are immature and contested. ^[18,20]
• Functional outcomes (employment, education, relationships) generally improve with social and medical transition in cohort data. ^[18]

Acute psychiatric risk in this population is driven mainly by suicidality, minority stress, and the medical complications of hormone therapy. The triage should look familiar to any psychiatrist, with two specific overlays: hormone-related medical emergencies and the access-disruption risk that follows policy or insurance changes.

Suicide risk

• Lifetime suicide attempt rates in transgender adults are reported around 30-40 percent in large surveys, well above the general-population baseline; current ideation and recent attempts are major triage drivers. ^[6,11]
• Family rejection, peer victimization, recent loss of access to care, and discontinuation of hormones are acute risk amplifiers. ^[6,11]
• Standard suicide-risk assessment applies; do not treat gender identity as a protective or a risk factor in itself — the distress, the supports, and the precipitants are what to assess. ^[3-4]

Acute agitation and inpatient considerations

• Inpatient units should use the patient's affirmed name and pronouns, place patients consistent with affirmed gender when safe to do so, and continue hormone therapy through admission unless medically contraindicated. ^[4]
• Abrupt cessation of cross-sex hormones during hospitalization can precipitate mood destabilization and worsened dysphoria; this is a frequent inpatient pitfall. ^[4,13]

Hormone-related medical emergencies

• Estrogen-related VTE, including pulmonary embolism, requires immediate workup and anticoagulation; estrogen should usually be held during the acute thrombotic period. ^[13]
• Testosterone-related erythrocytosis (hematocrit greater than approximately 54 percent) may precipitate thrombotic events and requires dose reduction or temporary discontinuation. ^[13]
• Acute estrogen overdose or self-administered high-dose regimens carry risk of severe hepatic and thrombotic complications and warrant emergency evaluation. ^[13]

Safety pearls

• Document affirmed name, pronouns, and legal name discrepancies clearly in the record to prevent misidentification. ^[4]
• Screen for intimate partner violence, sex work, and housing instability, which are elevated in this population and shape both safety planning and care continuity. ^[6,11]

Few areas in contemporary psychiatry have seen as much guideline divergence, regulatory turbulence, and public contestation as adolescent gender-affirming care. Clinicians should be familiar with the substantive debates without flattening them into a single position.

• The strength of the evidence supporting pubertal suppression and adolescent cross-sex hormones is contested; several European jurisdictions (United Kingdom, Sweden, Finland) have restricted or paused routine provision pending further evaluation, while major North American societies continue to endorse them within multidisciplinary care. ^[4,8,15,20]
• The Cass Review (NHS England, 2024) found low-certainty evidence for adolescent medical pathways and recommended a more cautious, research-embedded approach; its methodology and conclusions have been both praised and criticized in the academic literature. ^[20]
• The phenomenon described as "rapid-onset gender dysphoria" — a hypothesized adolescent-onset trajectory associated with peer-group and social-media influence — is debated; original survey methodology has been criticized, and the construct is not recognized in DSM-5-TR or ICD-11. ^[20]
• Detransition prevalence, drivers, and clinical implications are actively contested; methodologically rigorous prospective studies remain sparse. ^[18,20]
• Informed-consent models that streamline access to hormones by relaxing the gatekeeping role of mental-health assessment are increasingly adopted in adult care, with proponents emphasizing autonomy and access and critics emphasizing missed comorbidity. ^[4]
• The role of psychotherapy in adolescent care is debated, with disagreement over how to distinguish supportive exploration from inappropriate gatekeeping or, at the other extreme, from inappropriate steering toward medical transition. ^[3-4,20]
• Legal and regulatory landscapes are shifting rapidly in multiple countries, including bans or restrictions on adolescent care in several U.S. states and changes to NHS commissioning in the United Kingdom; clinicians should track local rules. ^[20]

• DSM-5-TR requires marked incongruence between experienced and assigned gender plus clinically significant distress or impairment for at least 6 months. ^[1]
• DSM-5 renamed "gender identity disorder" to gender dysphoria to depathologize identity and locate the diagnosis in the distress. ^[1]
• ICD-11 moved gender incongruence out of the mental disorders chapter into a new chapter on conditions related to sexual health. ^[2]
• WPATH Standards of Care, version 8 (2022) is the most widely referenced multidisciplinary framework for gender-affirming care across the lifespan. ^[4]
• The Endocrine Society guideline recommends pubertal suppression with GnRH analogues at Tanner stage 2 or later in appropriately selected adolescents. ^[4,15]
• Estrogen therapy carries dose-dependent VTE risk; transdermal estradiol is preferred over oral ethinyl estradiol in patients with elevated cardiovascular risk. ^[13]
• Testosterone monitoring includes hematocrit (watch for erythrocytosis above approximately 54 percent), lipids, liver enzymes, and blood pressure. ^[13]
• Suicide attempt rates in transgender adults are reported around 30-40 percent in large surveys, with family rejection a major modifiable risk factor. ^[6,11]
• Conversion or reparative approaches are explicitly contraindicated and associated with increased suicidality. ^[3-4,17]
• Regret after adult gender-affirming surgery is consistently reported under 2 percent in long-term cohorts. ^[16,18]
• Comorbid autism spectrum disorder is overrepresented in adolescent presentations and must be assessed concurrently. ^[4,8]
• The Cass Review (2024) found low-certainty evidence for adolescent medical pathways and prompted NHS England to restructure services. ^[20]
• Fertility preservation counseling is required before initiating pubertal suppression or cross-sex hormones. ^[4,13]
• The Utrecht Gender Dysphoria Scale and the Gender Identity/Gender Dysphoria Questionnaire for Adolescents and Adults are commonly used assessment tools. ^[13]
• Pubertal suppression is associated with attenuated bone mineral density accrual and uncertain long-term cognitive effects. ^[4,15]

No external funding. No conflicts of interest declared. Peer-review status: pending.